Title: Cilnidipine
CAS Registry Number: 132203-70-4
CAS Name: 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester
Additional Names: (±)-(E)-cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate
Manufacturers' Codes: FRC-8653
Trademarks: Atelec (Morishita); Cinalong (Fujirebio); Siscard (Boehringer, Ing.)
Molecular Formula: C27H28N2O7
Molecular Weight: 492.52
Percent Composition: C 65.84%, H 5.73%, N 5.69%, O 22.74%
Literature References: Dihydropyridine calcium channel blocker. Prepn: T. Kutsuma et al., EP 161877; eidem, US 4672068 (1985, 1987 both to Fujirebio). Pharmacology: K. Ikeda et al., Oyo Yakuri 44, 433 (1992). Mechanism of action study: M. Hosono et al., J. Pharmacobio-Dyn. 15, 547 (1992). LC-MS determn in plasma: K. Hatada et al., J. Chromatogr. 583, 116 (1992). Clinical study: M. Ishii, Jpn. Pharmacol. Ther. 21, 59 (1993). Acute toxicity study: S. Wada et al., Yakuri to Chiryo 20, Suppl. 7, S1683 (1992), C.A. 118, 32711 (1992).
Properties: Crystals from methanol, mp 115.5-116.6°. LD50 in male, female mice, rats (mg/kg): ³5000, ³5000, ³5000, 4412 orally; ³5000 all species s.c.; 1845, 2353, 441, 426 i.p. (Wada).
Melting point: mp 115.5-116.6°
Toxicity data: LD50 in male, female mice, rats (mg/kg): ³5000, ³5000, ³5000, 4412 orally; ³5000 all species s.c.; 1845, 2353, 441, 426 i.p. (Wada)
Therap-Cat: Antihypertensive.
Keywords: Antihypertensive; Dihydropyridine Derivatives; Calcium Channel Blocker; Dihydropyridine Derivatives.
Cilomilast Cimaterol Cimetropium Bromide Cimigenol Cinacalcet

Systematic (IUPAC) name
O3-(2-methoxyethyl) O5-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine- 3,5-dicarboxylate
Clinical data
AHFS/ International Drug Names
Legal status  ?
CAS number 132203-70-4
ATC code C08CA14
PubChem CID 5282138
ChemSpider 4445338
KEGG D01173
Chemical data
Formula C27H28N2O7 
Mol. mass 492.52 g/mol

Cilnidipine (INN) is a calcium channel blocker. It is sold as Atelec in Japan, & as CILACAR 5/10/20mg in India by JB CHEMICALS & PHARMACEUTICALS LTD (JBCPL) - UNIQUE. JBCPL first introduced Cilnidipine in India as CILACAR 5/10/20mg way back in 2007. Effects of Cilnidipine CILACAR 5/10/20mg compels to rethink on hypertension management. Cilnidipine CILACAR 5/10/20mg is the novel calcium antagonist accompanied with L-type and N-type calcium channel blocking function. It was jointly developed by Fuji Viscera Pharmaceutical Company, Japan and Ajinomoto, Japan and approved to come into market for the first time and used for high blood pressure treatment in 1995. Compared with other calcium antagonists, cilnidipine can act on the N-type calcium-channel that existing sympathetic nerve end besides acting on L-type calcium-channel that similar to most of the calcium antagonists. Due to its N-type calcium-channel blocking properties, it has more advantages compared to conventional calcium-channel blockers. It has lower incidence of Pedal edema, one of the major adverse effects of other calcium channel blockers. Cilnidipine has similar blood pressure lowering efficacy as compared to amlodipine. One of the distinct property of cilnidipine from amlodipine is that it does not cause reflex tachycardia.



L-type calcium channel blocker (Amlodipine) dilates the only arterioles & not the venules, hence blood pressure increases in the capillary bed and are thought to cause leg edema.

CILNIDIPINE due to its blocking action at N-type calcium channel dilates both arteriole & venules as a result the pressure in the capillary bed is reduces. The accumulated fluid in the tissues flows back to veins & thus Cilnidipine minimizes the incidence of pedal edema.


Cilnidipine controls hypertension for 24 hours with once daily dose. Cilnidipine has enhanced lipophilicity leading to prolonged antihypertensive effect correlated with occupancy of the binding site. In 24 hour clinical assessment, once-daily administration of cilnidipine (5–20 mg) produced BP reduction for 24 hour period. This indicates that once-daily cilnidipine exerts a sufficient and prolonged reduction of BP.2 Cilnidipine has 50 times higher selectivity for N-type of calcium channels than amlodipine. The inhibitory effect on the N-type Ca2+channel may bestow an additional clinical advantage for the treatment of hypertension, such as suppression of reflex tachycardia.3

As catecholamines induce platelet activation via alpha 2-receptors on platelet membrane, decrease in norepinephrine level by cilnidipine (absent in amlodipine) causes attenuation of platelet activation.

CILNIDIPINE significantly decreased urinary albumin excretion without affecting serum creatinine concentration in hypertensive patients.11 CILNIDIPINE CILACAR 5/10/20mg is superior to amlodipine in preventing the progression of proteinuria in patients with hypertension and chronic renal disease.1 CILNIDIPINE suppresses the development of proteinuria greater than amlodipine through inhibiting N-type calcium channel-dependent podocyte injury.12 CILNIDIPINE leads to less activation of the RAAS compared with amlodipine and therefore cilnidipine might be expected to be superior in organ protection in addition to the anti-albuminuric effect.13 Cilnidipine inhibits proliferation of vascular smooth muscle cells through inhibition of DNA/ RNA synthesis induced by growth-promoting factors released during atherosclerosis.

"PLEIOTROPIC EFFECTS CILNIDIPINE (CILACAR) COMPELS TO RETHINK ON HYPERTENSION MANAGEMENT Cilnidipine Improves baroreflex sensitivity, Improves NO availability, Ensures Antiproliferative effect, Inhibition of platelet activity, Exerts Antiarrhythmic effect, Reduction in Serum uric acid